Last reviewed · How we verify
Veregen
At a glance
| Generic name | Veregen |
|---|---|
| Sponsor | MediGene |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring (PHASE2)
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis (PHASE3)
- Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males (PHASE3)
- Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment (PHASE2)
- Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment (NA)
- Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study (PHASE4)
- Topical Green Tea Ointment in Treatment of Superficial Skin Cancer (PHASE2, PHASE3)
- Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |